The ALS-Reproducible Antibody Platform (ALS-RAP) Webinar

C9orf72 antibody
(GTX632041)

TDP43 antibody
(GTX114210)

SOD1 antibody
(GTX100554)

ATXN2 antibody
(GTX130329)

GeneTex is honored to host Dr. Carl Laflamme, a senior postdoctoral research fellow in the laboratory of the distinguished Dr. Peter McPherson at McGill University’s Montreal Neurological Institute. Dr. Laflamme’s work has focused on understanding the mechanisms underlying amyotrophic lateral sclerosis (ALS) with particular emphasis on C9orf72, a gene whose disruption represents the most common genetic cause of ALS/frontotemporal dementia (FTD). In addition, he is currently spearheading the ALS Reproducible Antibody Platform (ALS-RAP) that is dedicated to leveraging CRISPR/Cas9 knockout technology to identify reliable commercial antibodies for ALS/FTD research.

In his talk, Dr. Laflamme will discuss his published work describing the systematic assessment of antibodies against the C9ORF72 protein as part of ALS-RAP. He will then present intriguing data regarding C9ORF72 biology in macrophages, and will introduce his very exciting and potentially revolutionary efforts to expand the ALS-RAP methodology for antibodies against additional ALS disease proteins as well as those of other neurodegenerative disorders. Dr. Laflamme will explain how this approach will be further broadened and amplified to address the commercial antibody reliability crisis in biomedical research.

Topic: The ALS-Reproducible Antibody Platform (ALS-RAP): Identification of high-quality antibodies for ALS research

When:
Tues, June 8th, 2021 4pm